Related Experiment Video
Updated: Jan 19, 2026

Measuring Microbial Mutation Rates with the Fluctuation Assay
Published on: November 28, 2019
A 40-YEAR FOLLOW-UP OF A PATIENT WITH MULTIPLE PARAGANGLIOMAS AND A SDHD MUTATION
A Elenkova1, R Robeva1, A P Gimenez-Roqueplo2,3
1Medical University of Sofia Faculty of Medicine - Department of Endocrinology, USHATE "Acad. Ivan Penchev", Sofia, Bulgaria.
Germline mutations in the Succinate Dehydrogenase Complex Subunit D gene (SDHD) can cause multiple paragangliomas (PGLs). Multimodal treatment involving surgery, radiotherapy, and medication can achieve long-term disease control.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- Germline mutations in the Succinate Dehydrogenase Complex Subunit D gene (SDHD) are associated with paragangliomas (PGLs).
- SDHD-related PGLs are typically benign but can be multifocal.
Observation:
- A patient with a germline SDHD mutation developed multifocal PGLs over 40 years.
- Initial diagnosis at age 23 with a cervical PGL treated by surgery.
- Disease progression noted in 2013, despite prior radiotherapy in 2008.
Findings:
- A complex treatment regimen including surgery, radiotherapy, and Octreotide LAR was administered.
- This multimodal approach resulted in long-term clinical and biochemical remission.
- Tumor growth was effectively controlled.
Implications:
- Multicentric SDHD-related PGLs necessitate a multimodal treatment strategy.
- Combining surgery, radiotherapy, and medical therapy can achieve long-term disease control.
- This approach helps maintain a good quality of life for patients.
Related Concept Videos
07:44Measuring Microbial Mutation Rates with the Fluctuation Assay
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Mutations
08:57Aip1p Dynamics Are Altered by the R256H Mutation in Actin
13:57Assessing the Multiple Dimensions of Engagement to Characterize Learning: A Neurophysiological Perspective
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

